Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03773107 · OUTCOME

Clinical Benefit Rate

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)

What was measured

Clinical benefit will be determined for each subject as a binary variable indicating whether or not the subject achieved a best overall response of minimal response (MR) or better as determined by the IMWG criteria

Analysis population: Participants who initiate protocol-directed therapy and have measurable disease at baseline.

Groups in this outcome

Phase I 5m Ruxolitinib

Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 10 mg Ruxolitinib

Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 15 mg Ruxolitinib

Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I 5m Ruxolitinib5
Phase I 10 mg Ruxolitinib4
Phase I 15 mg Ruxolitinib3

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase I 5m Ruxolitinib1Not reportedNot reportedNot reportedNot reported
Phase I 10 mg Ruxolitinib2Not reportedNot reportedNot reportedNot reported
Phase I 15 mg Ruxolitinib1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    units
    Participants
description
Clinical benefit will be determined for each subject as a binary variable indicating whether or not the subject achieved a best overall response of minimal response (MR) or better as determined by the IMWG criteria
groups
  1. description
    Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG000
    title
    Phase I 5m Ruxolitinib
  2. description
    Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG001
    title
    Phase I 10 mg Ruxolitinib
  3. description
    Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG002
    title
    Phase I 15 mg Ruxolitinib
param Type
NUMBER
population Description
Participants who initiate protocol-directed therapy and have measurable disease at baseline.
reporting Status
POSTED
time Frame
Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)
title
Clinical Benefit Rate
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice